Win­ners and losers at #ES­MO18

MU­NICH — As­traZeneca has fol­lowed up on its break­through ap­proval for Lyn­parza — the first of the PARP wave that ar­rived on the mar­ket 4 years ago — with the roll­out of im­pres­sive front­line da­ta for ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER